Aspergillus PCR Early Detection in High Risk Oncohematological Patients

Inclusion Criteria: * Signature of informed consent to participate in the study. * Adult patients (\> 18 years), diagnosed with acute myelogenous leukemia or myelodysplastic syndrome with chemotherapy (CT) intensive, or admitted to undergo allogeneic hematopoietic progenitor cells, or transplantation with graft versus host disease. * The patient should be included in this protocol from the start of their chemotherapy or conditioning therapy as reflected in another section. Exclusion Criteria: * Employment of antifungal prophylaxis (30 days prior to inclusion) with triazole / polyene with activity against Aspergillus (itraconazole, voriconazole, posaconazole, amphotericin B inhalation). * Use of other systemic antifungal activity against Aspergillus (amphotericin, terbinafine, flucytosine, echinocandins, etc.). Therefore it will Fluconazole prophylaxis exclusively. * Background of IFI proven / probable prior * Probable IFI / tested at the time of inclusion in the study. * Exclusion will cause a lack of compliance with the inclusion criteria. * Patients who have a lack of follow biweekly with galactomannan or PCR. Have a bacterial infection not properly treated and controlled before starting empirical antifungal treatment (according to the definition given above). And finally they have a neutropenia of short duration that it creates a significant risk of IFI. This information will not be known logically to include the patient in the study.